Home Data Calendar Blog

YMAB

Tables

		2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31
Common Stock Value		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Weighted Average Number Of Diluted Shares Outstanding		43.78	NA	43.62	43.66	43.67	NA	43.72	43.72	43.71	NA	43.60	43.57	44.38	NA
Weighted Average Number Of Shares Outstanding Basic		43.78	NA	43.62	43.66	43.67	NA	43.72	43.72	43.71	NA	43.60	43.57	41.87	NA
Earnings Per Share Basic		-0.15	-0.02	-0.18	-0.14	-0.15	0.02	-0.63	-0.94	-0.64	-0.85	-0.66	-0.53	0.80	-0.48
Earnings Per Share Diluted		-0.15	-0.02	-0.18	-0.14	-0.15	0.02	-0.63	-0.94	-0.64	-0.85	-0.66	-0.53	0.75	-0.48

		2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31
Revenue From Contract With Customer Excluding Assessed Tax		19.93	23.36	20.45	20.75	20.25	31.45	12.54	10.80	10.49	9.60	8.96	10.95	5.38	20.75
Revenues		19.93	23.36	20.45	20.75	20.25	31.45	12.54	10.80	10.49	9.60	8.96	10.95	5.38	20.75
Cost Of Goods And Services Sold		2.10	2.04	2.60	4.65	2.08	2.02	2.48	1.14	1.83	1.46	0.55	0.20	0.09	NA
Costs And Expenses		26.84	26.56	28.20	27.97	27.75	32.60	38.55	50.74	38.18	45.36	37.67	33.66	33.64	40.84
Research And Development Expense		13.27	13.39	15.36	12.05	13.42	19.79	22.45	26.42	22.91	28.76	23.13	19.78	21.58	24.01
Selling General And Administrative Expense		11.43	11.13	10.20	11.27	12.25	10.79	13.63	23.08	13.44	15.14	13.99	13.47	11.97	14.63
Operating Income Loss		-6.91	-3.20	-7.75	-7.22	-7.50	-1.15	-26.02	-39.95	-27.70	-35.76	-28.70	-22.71	-28.26	-20.09
Allocated Share Based Compensation Expense		3.85	NA	NA	NA	5.30	NA	NA	NA	NA	NA	NA	NA	NA	NA
Income Tax Expense Benefit		0.16	0.20	0.19	0.18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Profit Loss		-6.63	-0.99	-7.75	-6.30	-6.39	1.16	-27.53	-41.13	-28.07	-36.89	-28.86	-22.94	33.41	-19.93
Net Income Loss		-6.63	-0.99	-7.75	-6.30	-6.39	1.16	-27.53	-41.13	-28.07	-36.89	-28.86	-22.94	33.41	-19.93
Comprehensive Income Net Of Tax		-6.23	-2.39	-6.94	-6.28	-6.70	-2.21	-25.93	-39.71	-27.76	-35.75	-28.62	-22.86	33.85	-20.43
Net Income Loss Available To Common Stockholders Basic		-6.63	-0.99	-7.75	-6.30	-6.39	1.16	-27.53	-41.13	-28.07	-36.89	-28.86	-22.94	33.41	-19.93
Net Income Loss Available To Common Stockholders Diluted		-6.63	-0.99	-7.75	-6.30	-6.39	1.16	-27.53	-41.13	-28.07	-36.89	-28.86	-22.94	33.41	-19.93

		2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31
Assets		123.31	127.87	128.88	132.40	137.44	141.46	143.91	165.18	191.05	212.78	239.98	259.48	274.92	132.05
Liabilities		24.13	26.88	28.73	27.71	29.62	32.23	36.02	33.78	33.58	32.68	29.13	25.16	22.70	26.21
Liabilities And Stockholders Equity		123.31	127.87	128.88	132.40	137.44	141.46	143.91	165.18	191.05	212.78	239.98	259.48	274.92	132.05
Stockholders Equity		99.19	100.98	100.15	104.68	107.83	109.22	107.90	131.40	157.47	180.11	210.84	234.32	252.22	105.84

		2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31
Assets Current		108.27	111.11	114.86	115.78	124.01	130.45	133.24	153.92	177.74	202.26	230.58	249.37	264.01	122.36
Cash And Cash Equivalents At Carrying Value		75.75	78.64	86.57	87.91	92.63	105.76	114.53	133.66	156.72	181.56	215.73	233.59	252.27	114.63
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents		75.75	78.64	86.57	87.91	92.63	105.76	114.53	133.66	156.72	181.56	215.73	233.59	252.27	114.63
Accounts Receivable Net Current		20.59	22.45	18.87	19.12	18.70	12.53	9.25	7.21	9.32	7.71	7.26	8.52	6.00	NA
Inventory Net		8.45	5.07	7.11	5.19	8.95	6.70	6.24	6.79	5.59	5.51	4.79	3.82	1.00	NA
Other Assets Current		3.48	4.96	2.30	3.57	3.73	5.45	3.23	6.25	6.10	7.47	2.80	3.44	4.74	7.73

		2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31
Property Plant And Equipment Net		0.15	0.22	0.30	0.38	0.51	0.60	1.37	1.55	1.70	1.85	1.85	1.92	2.10	1.82
Intangible Assets Net Excluding Goodwill		2.54	2.63	2.72	2.81	2.90	2.99	1.53	1.57	1.62	1.66	NA	NA	NA	NA
Other Assets Noncurrent		11.17	12.49	9.41	12.25	8.66	5.68	5.60	5.75	6.84	3.17	4.75	4.79	4.83	3.29

		2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31
Liabilities Current		17.61	20.13	21.81	24.23	25.92	28.28	32.02	29.45	29.04	27.88	25.36	20.99	17.00	19.54
Accounts Payable Current		6.73	6.06	7.61	7.25	8.84	14.18	13.72	11.29	14.66	13.55	11.02	6.80	6.54	9.37
Other Accrued Liabilities Current		0.71	0.42	0.74	0.45	0.32	0.41	1.52	0.27	1.44	1.42	0.64	1.00	0.99	0.33
Accrued Liabilities Current		9.99	13.17	13.30	16.15	16.22	13.24	17.09	17.07	12.93	12.54	12.49	12.17	8.49	8.20

		2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31
Other Liabilities Noncurrent		0.85	0.86	0.82	0.82	0.82	0.80	0.73	0.78	0.83	0.85	0.87	0.94	1.93	1.97
Operating Lease Liability Noncurrent		0.29	0.52	0.72	0.42	0.63	0.90	1.02	1.30	1.60	1.85	0.65	0.99	1.51	2.01

		2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31
Stockholders Equity		99.19	100.98	100.15	104.68	107.83	109.22	107.90	131.40	157.47	180.11	210.84	234.32	252.22	105.84
Common Stock Value		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Additional Paid In Capital		562.44	558.00	554.78	552.37	549.23	543.93	540.39	537.96	524.33	519.21	514.20	509.05	504.09	391.56
Retained Earnings Accumulated Deficit		-464.10	-457.47	-456.48	-448.74	-442.43	-436.04	-437.20	-409.67	-368.54	-340.48	-303.58	-274.72	-251.79	-285.20
Accumulated Other Comprehensive Income Loss Net Of Tax		0.85	0.45	1.85	1.04	1.02	1.33	4.70	3.10	1.68	1.37	0.23	-0.01	-0.09	-0.53

		2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31
Net Cash Provided By Used In Operating Activities		-3.48	-8.04	-1.34	-4.73	-13.12	-8.66	-19.23	-23.10	-24.93	-33.86	-18.08	-18.76	-31.86	-17.70
Net Cash Provided By Used In Financing Activities		0.59	NA	NA	NA	NA	0.00	0.05	0.00	0.03	0.10	0.25	0.13	107.83	1.42

		2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31
Net Cash Provided By Used In Operating Activities		-3.48	-8.04	-1.34	-4.73	-13.12	-8.66	-19.23	-23.10	-24.93	-33.86	-18.08	-18.76	-31.86	-17.70
Net Income Loss		-6.63	-0.99	-7.75	-6.30	-6.39	1.16	-27.53	-41.13	-28.07	-36.89	-28.86	-22.94	33.41	-19.93
Profit Loss		-6.63	-0.99	-7.75	-6.30	-6.39	1.16	-27.53	-41.13	-28.07	-36.89	-28.86	-22.94	33.41	-19.93
Depreciation Depletion And Amortization		0.16	0.16	0.17	0.22	0.18	0.23	0.23	0.19	0.20	0.29	0.14	0.22	0.13	0.12
Increase Decrease In Accounts Receivable		-1.87	3.58	-0.24	0.42	6.17	3.28	2.04	-2.12	1.61	0.45	-1.25	2.52	6.00	NA
Increase Decrease In Inventories		3.38	-2.05	1.93	-3.76	2.24	0.46	-0.55	1.21	0.08	0.72	0.97	2.81	1.00	NA
Increase Decrease In Accounts Payable		0.18	-0.66	-0.05	-1.38	-4.77	-1.09	2.43	-3.37	1.11	2.53	4.22	0.26	-2.83	-0.95
Share Based Compensation		3.85	3.12	2.41	3.62	5.30	3.54	3.34	13.63	5.09	4.91	4.90	4.83	4.70	8.34

		2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31
Net Cash Provided By Used In Financing Activities		0.59	NA	NA	NA	NA	0.00	0.05	0.00	0.03	0.10	0.25	0.13	107.83	1.42

		2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31
Revenues		19.93	23.36	20.45	20.75	20.25	31.45	12.54	10.80	10.49	9.60	8.96	10.95	5.38	20.75
Adium Pharma S.a, License, Distribution Arrangement		0.50	0.00	0.50	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Adium Pharma S.a, Subsequent Event, Distribution Arrangement		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Wep Clinical Limited, Product, Non Us, Distribution Arrangement		NA	3.04	3.05	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
License		0.50	0.00	0.50	NA	NA	15.00	0.00	1.00	NA	0.00	0.00	2.00	NA	20.00
Product		19.43	23.36	19.95	20.75	20.25	16.45	12.54	9.80	NA	9.60	8.96	8.95	5.38	NA
Royalty, Sales Channel Through Intermediary		0.46	0.64	0.43	NA	0.66	0.71	0.06	NA	NA	NA	NA	NA	NA	NA
Product,US		18.61	19.06	16.07	NA	16.83	15.39	12.42	NA	NA	NA	NA	NA	NA	NA
Product, Non Us		0.82	4.30	3.88	NA	3.42	1.06	0.12	NA	NA	NA	NA	NA	NA	NA
Revenue From Contract With Customer Excluding Assessed Tax		19.93	23.36	20.45	20.75	20.25	31.45	12.54	10.80	10.49	9.60	8.96	10.95	5.38	20.75
Adium Pharma S.a, License, Distribution Arrangement		0.50	0.00	0.50	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Adium Pharma S.a, Subsequent Event, Distribution Arrangement		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Wep Clinical Limited, Product, Non Us, Distribution Arrangement		NA	3.04	3.05	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
License		0.50	0.00	0.50	NA	NA	15.00	0.00	1.00	NA	0.00	0.00	2.00	NA	20.00
Product		19.43	23.36	19.95	20.75	20.25	16.45	12.54	9.80	NA	9.60	8.96	8.95	5.38	NA
Royalty, Sales Channel Through Intermediary		0.46	0.64	0.43	NA	0.66	0.71	0.06	NA	NA	NA	NA	NA	NA	NA
Product,US		18.61	19.06	16.07	NA	16.83	15.39	12.42	NA	NA	NA	NA	NA	NA	NA
Product, Non Us		0.82	4.30	3.88	NA	3.42	1.06	0.12	NA	NA	NA	NA	NA	NA	NA

Plots across concepts

Line plots across dimensions of each concept